Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C. by Sarkar, Souvik et al.
UC Davis
UC Davis Previously Published Works
Title
Colitis Following Initiation of Sofosbuvir and Simeprevir for Genotype 1 Hepatitis C.
Permalink
https://escholarship.org/uc/item/2k4635qw
Journal
ACG Case Reports Journal, 3(1)
ISSN
2326-3253
Authors
Sarkar, Souvik
Mitchell, Kisha
Lim, Joseph
et al.
Publication Date
2015-10-01
DOI
10.14309/crj.2015.96
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
ACG CASE REPORTS JOURNAL
acgcasereports.gi.org ACG Case Reports Journal | Volume 3 | Issue 1 | October 201542
CASE REPORT | COLON
Colitis Following Initiation of Sofosbuvir and Simeprevir for 
Genotype 1 Hepatitis C
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and Simona Jakab, MD1 
1Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT
2Department of Pathology, Yale University School of Medicine, New Haven, CT
3IBD Center, Mount Sinai Beth Israel, New York, NY 
Abstract
Sofosbuvir and simeprevir are used for the treatment of chronic hepatitis C (HCV) genotype 1. Both drugs have 
been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% with sofosbuvir plus simeprevir, and 
0% with simeprevir. No prior reports exist of colitis secondary to either drug or their combination. We report a 
patient with no prior history of inflammatory bowel disease who developed significant bloody diarrhea within 2 
weeks of sofosbuvir/simeprevir initiation. Colonoscopy and biopsy confirmed pancolitis, which responded to 
mesalamine and completion of sofosbuvir/simeprevir.
Introduction
Hepatitis C virus (HCV) infection poses a significant public health challenge with substantial morbidity and mor-
tality. New interferon-free therapies have excellent sustained virologic response rates (SVRs; >90%) with minimal 
side effects.1,2 The U.S. Food and Drug Administration recently approved the combination of sofosbuvir, a NS5B 
polymerase inhibitor, and simeprevir, a NS3 protease inhibitor, for the treatment of chronic HCV genotype 1. 
Sofosbuvir and simeprevir have been well-tolerated, with diarrhea noted in 6% cases with sofosbuvir, 16% cases 
with sofosbuvir/simeprevir, and 0% with simeprevir.1-3 No prior reports of colitis or exacerbation of chronic colitis 
secondary to either drug or their combination exist in MEDLINE, EMBASE, or post-marketing safety records. 
Case Report
A 50-year-old Hispanic man with HCV genotype 1 and well-compensated cirrhosis was evaluated for retreatment of 
HCV. He was a responder/relapser to telaprevir, pegylated interferon, and ribavirin, but otherwise had an unremark-
able medical history. He was a non-smoker with remote history of alcohol use, unremarkable family history, no known 
allergies, and was not taking any prescribed medications or supplements. He was interferon-ineligible due to throm-
bocytopenia, and started treatment with sofosbuvir 400 mg and simeprevir 150 mg daily. After 2 weeks of treatment, 
he noted increased flatulence and loose stool with intermittent blood. This was presumed to be self-limited, and a 
possible side effect of sofosbuvir/simeprevir, but worsened over the following 2 weeks. Stool studies for Clostridium 
difficile, bacterial culture, and ova and parasites were negative. Serum albumin was 4 g/dL, and electrolytes, blood 
panel, and coagulation laboratory tests were normal, except for low platelets at baseline. He underwent sigmoidos-
copy, which revealed erythematous friable mucosa without skip areas, with chronic active colitis on biopsy (Figure 1). 
 
Sofosbuvir/simeprevir was continued, but given persistent bloody diarrhea, he underwent colonoscopy at week 9 of 
therapy. This showed persistent, mild to moderate chronic colitis (Figure 2). Terminal ileum was unremarkable both 
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endoscopically and histologically. On week 10 of therapy, he 
was initiated on 2.4 g mesalamine once daily, with resolution 
of his diarrhea over the following 2 weeks. He remained clini-
cally asymptomatic on mesalamine, and achieved SVR. Seven 
months after completion of sofosbuvir/simeprevir treatment, 
but with the patient still taking mesalamine, repeat colonoscopy 
demonstrated normal mucosa macroscopically with minimal 
inflammatory changes on colonic mucosa and focal minimal 
non-specific ileitis (Figure 3). Serologic and genetic testing was 
performed using the PROMETHEUS® IBD sgi Diagnostic™ test 
(Prometheus Laboratories, Inc., San Diego, CA). The results 
revealed a possible predisposition to IBD, specifically Crohn’s 
disease. 
Discussion
Neither drug-induced colitis nor the development of chron-
ic colitis triggered by sofosbuvir, simeprevir, or sofosbuvir/
simeprevir has been previously described. Testing of our 
patient would suggest genetic predisposition for IBD, and 
we hypothesize that colitis may have been triggered on 
initiation of sofosbuvir and/or simeprevir.4 A wide variety 
of drugs have been implicated in drug-induced colitis pre-
senting with a heterogeneous array of clinical, endoscopic, 
and pathologic findings without a clear understanding of 
the pathophysiologic mechanism.5 Drug-induced colitis is 
sometimes difficult to discern from other etiologies of colitis. 
Our patient had mild to moderate symptoms and responded 
very well to mesalamine, allowing completion of sofosbuvir/
simeprevir. As sofosbuvir and sofosbuvir/simeprevir regi-
mens are used more frequently, more cases of diarrhea may 
be reported. Patients with persistent or bloody diarrhea post-
initiation of sofosbuvir- and/or simeprevir-based regimens 
should be adequately investigated for IBD-like colitis and 
managed appropriately.
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Figure 1. Endoscopic and microscopic images of the colon indicative of chronic active colitis at week 4 of sofosbuvir/simeprevir therapy. (A, B) Erythema-
tous friable mucosa with exudates without skip areas. (C) Marked increase in lamina propria lymphoplasmacytic inflammatory infiltrate, significant basal 
lymphoplasmacytosis with reactive lymphoid aggregates, mucosal distortion, lamina propria neutrophils, acute cryptitis, crypt abscesses, and surface 
damage suggestive of erosions. 
A B C
Figure 2. Endoscopic and microscopic images of the colon at week 9 of sofosbuvir/simeprevir. (A, B) Mild erythema in the cecum, with moderate erythema 
friability with few exudates in the rectosigmoid colon and loss of vascular pattern. (C) Crypt destruction with mucosal erosion-active colitis.
A B C
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Figure 3. Endoscopic and microscopic images of the colon 28 weeks after completion of sofosbuvir/simeprevir. (A, B) Normal mucosa. (C) Reactive colonic 
mucosa with minimal inflammatory changes.
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